The global in vitro lung model market size was estimated at around USD 310.82 million in 2023 and it is projected to hit around USD 1,552.53 million by 2033, growing at a CAGR of 17.45% from 2024 to 2033.
The in vitro lung model market presents a dynamic landscape within the biomedical research, pharmaceutical development, and respiratory health studies. This market is characterized by the emergence of innovative technologies and methodologies aimed at replicating the intricate complexities of the human lung in an in vitro setting. As a pivotal component of modern research, the in vitro lung model market plays a crucial role in advancing our understanding of respiratory diseases and fostering efficient drug development processes.
The growth of the in vitro lung model market is propelled by several key factors that collectively contribute to its expanding influence in biomedical research and pharmaceutical development. One significant driver is the escalating incidence of respiratory diseases globally, prompting an increased demand for advanced in vitro models. These models, leveraging technologies like cell culture systems, microfluidic devices, and biomimetic scaffolds, allow for the meticulous simulation of the complex physiological conditions of the human lung. Moreover, the market benefits from a surge in collaborations and partnerships among research institutions, pharmaceutical companies, and technology providers, fostering innovation and accelerating advancements in the field. Regulatory emphasis on alternatives to traditional testing methods, coupled with continuous technological advancements, further enhances the market's prospects. As the industry addresses challenges related to standardization and reproducibility, the in vitro lung model market is poised for sustained growth, offering a promising avenue for ethical and compliant research practices in the exploration of respiratory health and drug development.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 17.45% |
Market Revenue by 2033 | USD 1,552.53million |
Revenue Share of North America in 2023 | 45% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
2D model types segment dominated the market with a revenue share of 62% in 2023 due to their convenience, efficiency, and comprehensive nature. 2D models have been relatively simple to set up and maintain, making them accessible to a wide range of researchers, which helps in understanding tissue engineering or complex culture systems. Furthermore, 2D cultures are well-suited for high throughput screening, allowing researchers to test a large number of compounds or conditions in a relatively short time. Thus, high throughput screening plays a pivotal role in the dominance of this segment.
The 3D model segment is anticipated to grow at the fastest CAGR from 2024 to 2033 owing to its ability to mimic the 3D structure of lungs, including complex interactions between different cell types, the extracellular matrix, and the spatial distribution of cells. Moreover, 3D models allow researchers to recreate the in vitro microenvironment of the lung to a greater extent than 2D models, thus with such advantages over 2D models, the 3D model is expected to witness a lucrative growth in the coming years.
Drug discovery and toxicology studies segment dominated the global market in 2023. In vitro lung models provide a highly controlled and efficient platform for drug screening, which helps pharmaceutical companies and researchers to develop potential drugs to tackle the rising prevalence of respiratory diseases. Moreover, the growing ethical and regulatory push to reduce and replace animal testing further drives the importance of in vitro models in drug development and toxicology studies.
The 3D model development segment is anticipated to grow at the fastest CAGR from 2024 to 2033. 3D model provides a more accurate representation of the three-dimensional architecture and complexity of the human lung compared to 2D models. This increased physiological relevance, which is crucial for understanding lung biology and disease mechanisms, makes them a reliable model to study complex lung structures. Thus, with such parameters the demand for 3D models has increased, contributing to segment growth.
The pharmaceutical & biotechnology companies end-use segment led the market in 2023 due to their critical role in drug development and research. The pharmaceutical and biotechnology companies rely on in vitro lung models to evaluate the safety and efficacy of new drugs, since they are crucial tools for screening potential drug candidates. Moreover, the high throughput screening capability of in vitro lung models assists pharmaceutical and biotechnology companies in efficiently evaluating numerous potential drugs within a short timeframe further driving the segment dominance.
On the other hand, the academic and research institutes segment is projected to exhibit the fastest growth from 2024 to 2033 due to its pivotal role in advancing scientific understanding and developing novel therapies for respiratory diseases. Moreover, academic institutions use in vitro lung models for teaching and training purposes, to educate the next generation of scientists, researchers, and healthcare professionals. Thus, teaching and training further drive the adoption of in vitro lung models in academic settings.
North America dominated the market with largest market share of 45% in 2023. Increasing research onlung disorders is likely to create growth opportunities for the market within the region. For instance, according to the International Agency for Research on Cancer’s (IARC) GLOBOCAN, the region reported 254,000 cases of lung cancer in 2020 and is estimated to increase the number by 352,000 till 2040. Thus, such a high number of lung cancers in the region boosts the overall market growth.
Moreover, the presence of a significant number of pharmaceutical and biotechnology companies, as well as academic research institutions further drives the regional market growth. Asia Pacific is expected to register lucrative growth from 2023 to 2032 due to the development of healthcare as well as R&D infrastructure, increased investment in R&D in the region, and improvement in the regulatory framework in developing economies, such as Australia and India among others.
ImmuONE raised USD 2.48 million in November 2023 to create a lung model as a substitute for using animals in drug testing. This is anticipated to grow the clientele for the business.
BICO subsidiaries CELLINK, MatTek, and Visikol announced a joint venture in September 2021 that sought to create a contract research organization (CRO) that provided comprehensive bioprinting services. Through their combined efforts, the three organizations are able to give their consumers comprehensive services because of their combined knowledge. Through this partnership, CELLINK, MatTek, and Visikol give their customers access to a variety of services provided by all three companies.
By Type
By Application
By End-use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on In Vitro Lung Model Market
5.1. COVID-19 Landscape: In Vitro Lung Model Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global In Vitro Lung Model Market, By Type
8.1. In Vitro Lung Model Market, by Type, 2024-2033
8.1.1 2D Model
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. 3D Model
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global In Vitro Lung Model Market, By Application
9.1. In Vitro Lung Model Market, by Application, 2024-2033
9.1.1. Drug Discovery & Toxicology Studies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Physiological Research
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. 3D Model Development
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global In Vitro Lung Model Market, By End-use
10.1. In Vitro Lung Model Market, by End-use, 2024-2033
10.1.1. Academic Research Institutes
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global In Vitro Lung Model Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. Epithelix.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. MATTEK.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Lonza.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Emulate.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AlveoliX AG.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Nortis
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CN Bio Innovations Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. MIMETAS
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. InSphero.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. ATTC Global
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms